Springer Science and Business Media LLC
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Real-world Management of CML: Outcomes and Treatment Patterns
Springer Science and Business Media LLC - Tập 18 - Trang 167-175 - 2023
Chronic myeloid leukemia (CML) is a disease that previously signified a poor
prognosis, but treatment options and outcomes have improved over the last
several decades. Despite this, challenges remain in optimal management in
clinical practice, as the characteristics in trial populations differ from
patients who are treated in a real-world setting. This review describes recent
updates in real-world...
MRD in ALL: Optimization and Innovations
Springer Science and Business Media LLC - Tập 17 - Trang 69-81 - 2022
Measurable residual disease (MRD) is an important monitoring parameter that can
help predict survival outcomes in acute lymphoblastic leukemia (ALL).
Identifying patients with MRD has the potential to decrease the risk of relapse
with the initiation of early salvage therapy and to help guide decision making
regarding allogeneic hematopoietic cell transplantation. In this review, we
discuss MRD in ...
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances
Springer Science and Business Media LLC - Tập 11 - Trang 385-394 - 2016
While the majority of children and adolescents with newly diagnosed childhood
acute lymphoblastic leukemia (ALL) will be cured, as many as 20 % of patients
will experience relapse. On current treatment regimens, the intensity of upfront
treatment is stratified based upon prognostic factors with the aim of improving
cure rates (for those at the highest risk of relapse) and minimizing
treatment-rela...
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Springer Science and Business Media LLC - - 2021
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia
Springer Science and Business Media LLC - Tập 15 - Trang 294-304 - 2020
Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy. Advances in
multi-agent chemotherapy have resulted in dramatic improvements in the number of
pediatric cases that result in a cure; however, until recently, treatment
options for older adults or patients with relapsed and refractory disease were
extremely limited. This review seeks to describe in greater detail a number of
emergi...
Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO
Springer Science and Business Media LLC - Tập 14 - Trang 543-549 - 2019
MDS/MPNs comprise a group of rare hematologic malignancies that balance features
of myeloproliferation and bone marrow failure. Given overlapping clinical
features and rarity of incidence, MDS/MPNs have long posed a diagnostic and
therapeutic challenge. Herein, we sought to review recent advances in diagnosis
and emerging therapeutic strategies and highlight the upcoming ABNL MARRO study
which aim...
Standardizing the Initial Evaluation for Myelodysplastic Syndromes
Springer Science and Business Media LLC - Tập 8 - Trang 361-369 - 2013
The myelodysplastic syndromes (MDS) pose a unique diagnostic challenge for
clinicians and pathologists due to the clinicopathologic heterogeneity of the
disease and overlapping features with other benign and malignant disorders.
Currently, the initial evaluation of a patient with suspected MDS centers around
a detailed medical history, review of the peripheral blood and bone marrow by an
expert he...
Molecular Testing in Patients with Suspected Myelodysplastic Syndromes
Springer Science and Business Media LLC - Tập 11 - Trang 441-448 - 2016
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal
hematologic malignancies characterized by a hypercellular bone marrow and
morphologic dysplasia in one or more lineage (i.e., myeloid, erythroid, or
megakaryocytic), presenting clinically with leukopenia, anemia, and/or
thrombocytopenia and with a propensity to transform to acute myelogenous
leukemia. Newer technologies such ...
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia
Springer Science and Business Media LLC - Tập 1 - Trang 69-74 - 2006
Hydroxyurea is an old drug that is often used to control essential
thrombocythemia and polycythemia vera in patients with high-risk disease. It is
usually well tolerated and cheap and has been proven effective in many studies
for the prevention of thrombohemorrhagic complications associated with these
disorders. However, many clinicians are reluctant to use it because of the
perceived risk of prog...
Tổng số: 577
- 1
- 2
- 3
- 4
- 5
- 6
- 10